Ruan Qingmin, Lesort Mathieu, MacDonald Marcy E, Johnson Gail V W
Department of Psychiatry, University of Alabama at Birmingham, Birmingham, AL 35294-0017, USA.
Hum Mol Genet. 2004 Apr 1;13(7):669-81. doi: 10.1093/hmg/ddh082. Epub 2004 Feb 12.
Extensive striatal neuronal loss occurs in Huntington's disease (HD), which is caused by an expanded polyglutamine tract in huntingtin (htt). Evidence suggests that mutant htt directly or indirectly compromises mitochondrial function, contributing to the neuronal loss. To determine the role of compromised mitochondrial function in the neuronal cell death in HD, immortalized striatal cells established from Hdh(Q7) (wild-type) and Hdh(Q111) (mutant) mouse knock-in embryos were treated with 3-nitropropionic acid (3-NP), a mitochondrial complex II toxin. 3-NP treatment caused significantly greater cell death in mutant striatal cells compared with wild-type cells. In contrast, the extent of cell death induced by rotenone, a complex I inhibitor, was similar in both cell lines. Although evidence of apoptosis was present in 3-NP-treated wild-type striatal cells, it was absent in 3-NP-treated mutant cells. 3-NP treatment caused a greater loss of mitochondrial membrane potential (deltapsim) in mutant striatal cells compared with wild-type cells. Cyclosporine A, an inhibitor of mitochondrial permeability transition pore (PTP), and ruthenium red, an inhibitor of the mitochondrial calcium uniporter, both rescued mutant striatal cells from 3-NP-induced cell death and prevented the loss of deltapsim. These data show that mutant htt specifically increases cell vulnerability to mitochondrial complex II inhibition and further switched the type of cell death induced by complex II inhibition from apoptosis to a non-apoptotic form, caused by mitochondrial membrane depolarization, probably initiated by mitochondrial calcium overload and subsequent PTP opening. These findings suggest that impaired mitochondrial complex II function in HD may contribute to non-apoptotic neuronal cell death.
亨廷顿舞蹈症(HD)会出现广泛的纹状体神经元损失,该病由亨廷顿蛋白(htt)中多聚谷氨酰胺序列的扩增引起。有证据表明,突变型htt直接或间接损害线粒体功能,导致神经元损失。为了确定线粒体功能受损在HD神经元细胞死亡中的作用,用线粒体复合物II毒素3-硝基丙酸(3-NP)处理从Hdh(Q7)(野生型)和Hdh(Q111)(突变型)小鼠基因敲入胚胎建立的永生化纹状体细胞。与野生型细胞相比,3-NP处理导致突变型纹状体细胞死亡显著增加。相反,复合物I抑制剂鱼藤酮诱导的细胞死亡程度在两种细胞系中相似。虽然在3-NP处理的野生型纹状体细胞中存在凋亡证据,但在3-NP处理的突变型细胞中不存在。与野生型细胞相比,3-NP处理导致突变型纹状体细胞线粒体膜电位(ΔΨm)损失更大。线粒体通透性转换孔(PTP)抑制剂环孢菌素A和线粒体钙单向转运体抑制剂钌红均可使突变型纹状体细胞免受3-NP诱导的细胞死亡,并防止ΔΨm的损失。这些数据表明,突变型htt特异性增加细胞对线粒体复合物II抑制的易感性,并进一步将复合物II抑制诱导的细胞死亡类型从凋亡转变为非凋亡形式,这是由线粒体膜去极化引起的,可能由线粒体钙超载和随后的PTP开放引发。这些发现表明,HD中线粒体复合物II功能受损可能导致非凋亡性神经元细胞死亡。